A Milestone Moment: FDA Approves Addyi® for Hypoactive Sexual Desire Disorder in Postmenopausal Women
December 17, 2025
Brand Name :
Norpace
(United States) [Available] ,Norpace CR
(United States) [Available]Synonyms :
Class :
Antidysrhythmics, Ia
Dosage Forms & Strengths
capsule
100mg
150mg
Capsule-CR
100mg
150mg
Dosage Forms & Strengths
Capsule
100mg
150mg
Capsule-ER
100mg
150mg
It may enhance QTc interval when combined with erythromycin stearate
It may enhance QTc interval when combined with perphenazine
It may enhance QTc interval when combined with epinephrine
when both drugs are combined, there may be an increase in qtc interval
when both drugs are combined, there may be increased toxicity of disopyramide by QTC interval
It may enhance QTc interval when combined with pentamidine
It may enhance QTc interval when combined with efavirenz
QTc interval is increased both by lenvatinib and azithromycin
both lapatinib and disopyramide increase the QTc interval
CYP3A strong enhancers of the small intestine may reduce the bioavailability of disopyramide
disopyramide: they may diminish the serum concentration of CYP3A4 Inducers
disopyramide: they may diminish the serum concentration of CYP3A4 Inducers
disopyramide: they may diminish the serum concentration of CYP3A4 Inducers
disopyramide: they may diminish the serum concentration of CYP3A4 Inducers
disopyramide: they may diminish the serum concentration of CYP3A4 Inducers
disopyramide: they may increase the bradycardic effect of Beta-Blockers
when bromazepam and disopyramide are used together, there is a potential reduction in the bromazepam's metabolism
When helometasone is used together with disopyramide, this leads to elevated risk or seriousness of hyperglycemia
When disopyramide is used together with givinostat, this leads to enhanced risk or seriousness of Qtc prolongation
disopyramide leads to a reduction in the rate of excretion of nitric oxide, which leads to an increased level of serum
When disopyramide is used together with diazoxide, this leads to reduction in therapeutic effectiveness of disopyramide
methylprednisolone hemisuccinate
When methylprednisolone hemisuccinate is aided with disopyramide, this leads to elevated hyperglycemia risk
the effect of disopyramide is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
may enhance the serum concentration of CYP3A4 inhibitors
the activity of disopyramide may be increased due to pharmacodynamic synergism
the risk of hyperglycemia may be increased
When disopyramide is aided by hesperetin, it reduces hesperetin’s metabolism
Adverse drug reactions:
Frequency Defined
1-10%
Urinary urgency
Urinary retention
Dry throat
Hypokalemia
Muscle weakness
Muscular pain
Dyspnea
Impotence
Weight gain
Flatulence
Anorexia
Vomiting
Nausea
Dermatoses
Pruritus
Generalized rash
Increased triglycerides and cholesterol
Blurred vision
Pregnancy warnings:
Pregnancy category: C
Breastfeeding warnings:
crosses into breast milk
Pregnancy Categories:
Patient Information Leaflet
Generic Name: disopyramide
Why do we use disopyramide?
Disopyramide belongs to the class Antidysrhythmics used to treat arrythmia